» Authors » Jouko Levijoki

Jouko Levijoki

Explore the profile of Jouko Levijoki including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 481
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Pollesello P, Levijoki J, Papp Z
J Cardiovasc Pharmacol . 2025 Jan; PMID: 39847544
Positive inotropic responses upon administration of milrinone, an inhibitor of the phosphodiesterase enzyme (PDE), involve a well-pronounced positive chronotropic effect. Here we tested whether milrinone evokes this chronotropic response solely...
2.
Levijoki J, Saloranta L, Tuunainen J, Kaskinoro J, Pappinen S, Nourry S, et al.
J Pharmacol Exp Ther . 2023 Jan; 384(3):439-444. PMID: 36635086
Cancer treatments are frequently associated with nausea and vomiting despite greatly improved preventive medication. Administration of antinausea agents as eye drops might provide easy and rapid access to the systemic...
3.
Toth N, Loewe A, Szlovak J, Kohajda Z, Bitay G, Levijoki J, et al.
Sci Rep . 2022 Dec; 12(1):21830. PMID: 36528651
Sinus node (SN) pacemaking is based on a coupling between surface membrane ion-channels and intracellular Ca-handling. The fundamental role of the inward Na/Ca exchanger (NCX) is firmly established. However, little...
4.
Tuunainen J, Saloranta L, Levijoki J, Lindstedt J, Lehtisalo J, Pappinen S, et al.
Pharmaceuticals (Basel) . 2022 May; 15(5). PMID: 35631356
Naloxone as emergency treatment for opioid overdosing can be administered via several routes. However, the available administration methods are invasive or may be associated with incomplete or slow naloxone absorption....
5.
Levijoki J, Pollesello P, Grossini E, Papp Z
J Cardiovasc Pharmacol . 2022 Feb; 79(6):827-832. PMID: 35170487
OR-1855 and OR-1896 are 2 hemodynamically active metabolites of the inodilator levosimendan, with calcium sensitizing activity, but their mechanism of action is still not fully understood. It has been previously...
6.
Szlovak J, Tomek J, Zhou X, Toth N, Veress R, Horvath B, et al.
J Mol Cell Cardiol . 2020 Dec; 153:111-122. PMID: 33383036
Repolarization alternans, a periodic oscillation of long-short action potential duration, is an important source of arrhythmogenic substrate, although the mechanisms driving it are insufficiently understood. Despite its relevance as an...
7.
Otsomaa L, Levijoki J, Wohlfahrt G, Chapman H, Koivisto A, Syrjanen K, et al.
Br J Pharmacol . 2020 Sep; 177(24):5534-5554. PMID: 32959887
Background And Purpose: The lack of selective sodium-calcium exchanger (NCX) inhibitors has hampered the exploration of physiological and pathophysiological roles of cardiac NCX 1.1. We aimed to discover more potent...
8.
Kohajda Z, Toth N, Szlovak J, Loewe A, Bitay G, Gazdag P, et al.
Front Pharmacol . 2020 Feb; 10:1632. PMID: 32063850
Background And Purpose: The exact mechanism of spontaneous pacemaking is not fully understood. Recent results suggest tight cooperation between intracellular Ca handling and sarcolemmal ion channels. An important player of...
9.
Primessnig U, Bracic T, Levijoki J, Otsomaa L, Pollesello P, Falcke M, et al.
Eur J Heart Fail . 2019 Nov; 21(12):1543-1552. PMID: 31762174
Aims: Heart failure with preserved ejection fraction (HFpEF) is increasingly common but there is currently no established pharmacological therapy. We hypothesized that ORM-11035, a novel specific Na /Ca exchanger (NCX)...
10.
Hegyi B, Bossuyt J, Griffiths L, Shimkunas R, Coulibaly Z, Jian Z, et al.
Proc Natl Acad Sci U S A . 2018 Mar; 115(13):E3036-E3044. PMID: 29531045
Heart failure (HF) following myocardial infarction (MI) is associated with high incidence of cardiac arrhythmias. Development of therapeutic strategy requires detailed understanding of electrophysiological remodeling. However, changes of ionic currents...